X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (47604) 47604
Book Review (5181) 5181
Publication (2949) 2949
Newsletter (2358) 2358
Conference Proceeding (430) 430
Newspaper Article (180) 180
Book Chapter (175) 175
Dissertation (167) 167
Magazine Article (45) 45
Government Document (31) 31
Trade Publication Article (12) 12
Book / eBook (11) 11
Transcript (10) 10
Web Resource (9) 9
Paper (4) 4
Reference (4) 4
Data Set (2) 2
Journal / eJournal (1) 1
Presentation (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (35731) 35731
humans (30612) 30612
paclitaxel (30318) 30318
female (19615) 19615
oncology (17876) 17876
chemotherapy (13013) 13013
cancer (12270) 12270
paclitaxel - administration & dosage (12170) 12170
middle aged (12143) 12143
aged (10690) 10690
male (10265) 10265
antineoplastic combined chemotherapy protocols - therapeutic use (8832) 8832
animals (8763) 8763
adult (8447) 8447
paclitaxel - pharmacology (6956) 6956
treatment outcome (6776) 6776
pharmacology & pharmacy (6094) 6094
cell line, tumor (5262) 5262
cisplatin (5245) 5245
paclitaxel - therapeutic use (5017) 5017
research (4898) 4898
mice (4724) 4724
breast neoplasms - drug therapy (4709) 4709
care and treatment (4666) 4666
taxol (4662) 4662
breast cancer (4481) 4481
carboplatin (4074) 4074
therapy (3926) 3926
docetaxel (3879) 3879
apoptosis (3871) 3871
paclitaxel - adverse effects (3724) 3724
carcinoma (3696) 3696
ovarian neoplasms - drug therapy (3691) 3691
lung neoplasms - drug therapy (3673) 3673
analysis (3602) 3602
ovarian cancer (3537) 3537
antineoplastic combined chemotherapy protocols - adverse effects (3460) 3460
nanoparticles (3436) 3436
trial (3390) 3390
carboplatin - administration & dosage (3277) 3277
neoplasm staging (3205) 3205
drug delivery systems (3103) 3103
tumors (3076) 3076
aged, 80 and over (3003) 3003
drugs (2968) 2968
doxorubicin (2959) 2959
antineoplastic agents - therapeutic use (2946) 2946
antineoplastic agents, phytogenic - administration & dosage (2937) 2937
drug administration schedule (2924) 2924
antineoplastic agents (2907) 2907
cisplatin - administration & dosage (2905) 2905
antineoplastic agents, phytogenic - pharmacology (2860) 2860
breast neoplasms - pathology (2807) 2807
survival (2802) 2802
carcinoma, non-small-cell lung - drug therapy (2775) 2775
antineoplastic agents - pharmacology (2769) 2769
disease-free survival (2757) 2757
antimitotic agents (2666) 2666
drug therapy (2662) 2662
dose-response relationship, drug (2646) 2646
expression (2622) 2622
metastasis (2578) 2578
antineoplastic agents, phytogenic - therapeutic use (2572) 2572
prognosis (2520) 2520
in-vitro (2509) 2509
health aspects (2452) 2452
apoptosis - drug effects (2425) 2425
time factors (2410) 2410
medicine & public health (2329) 2329
breast-cancer (2272) 2272
retrospective studies (2268) 2268
gemcitabine (2249) 2249
cardiac & cardiovascular systems (2243) 2243
obstetrics & gynecology (2224) 2224
survival rate (2216) 2216
biochemistry & molecular biology (2213) 2213
paclitaxel - analogs & derivatives (2192) 2192
combination (2131) 2131
antineoplastic agents - administration & dosage (2125) 2125
taxoids (2123) 2123
paclitaxel - chemistry (2097) 2097
combined modality therapy (2095) 2095
deoxycytidine - analogs & derivatives (2074) 2074
ovarian neoplasms - pathology (2074) 2074
antineoplastic combined chemotherapy protocols - administration & dosage (2054) 2054
cells (2053) 2053
survival analysis (2038) 2038
drug resistance, neoplasm (1997) 1997
cancer therapies (1985) 1985
clinical trials (1969) 1969
lung neoplasms - pathology (1938) 1938
surgery (1931) 1931
cell survival - drug effects (1914) 1914
article (1904) 1904
cell biology (1892) 1892
follow-up studies (1874) 1874
abridged index medicus (1868) 1868
phase-ii (1815) 1815
neoplasms - drug therapy (1812) 1812
chemistry, multidisciplinary (1807) 1807
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (47869) 47869
Japanese (965) 965
Chinese (573) 573
French (377) 377
German (305) 305
Korean (165) 165
Spanish (137) 137
Russian (76) 76
Italian (65) 65
Polish (41) 41
Portuguese (38) 38
Hungarian (27) 27
Czech (22) 22
Turkish (16) 16
Dutch (15) 15
Danish (5) 5
Hebrew (5) 5
Swedish (5) 5
Croatian (4) 4
Lithuanian (4) 4
Finnish (3) 3
Slovak (3) 3
Slovenian (2) 2
Bulgarian (1) 1
Norwegian (1) 1
Persian (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Biomaterials, ISSN 0142-9612, 09/2017, Volume 140, pp. 162 - 169
In the latest trend of anticancer chemotherapy research, there were many macromolecular anticancer drugs developed based on enhanced permeability and retention... 
Liposome | Micelle | Human serum albumin | Nitric oxide | Enhanced permeability and retention effect | Nanoparticle albumin bound paclitaxel | MATERIALS SCIENCE, BIOMATERIALS | NAB-PACLITAXEL | ENGINEERING, BIOMEDICAL | DOXORUBICIN | TUMOR | VASCULAR-PERMEABILITY | ANTITUMOR DRUGS | DELIVERY | THERAPEUTIC-EFFICACY | IN-VIVO | NITRIC-OXIDE | ACCUMULATION | Neoplasms - metabolism | Paclitaxel - pharmacology | Pancreatic Neoplasms - metabolism | Humans | Melanoma, Experimental - drug therapy | Protein Multimerization | Capillary Permeability - drug effects | Male | Melanoma, Experimental - metabolism | Antineoplastic Agents - therapeutic use | Paclitaxel - pharmacokinetics | Pancreatic Neoplasms - drug therapy | Albumins - therapeutic use | Nitroso Compounds - pharmacology | Albumin-Bound Paclitaxel - pharmacokinetics | Albumin-Bound Paclitaxel - therapeutic use | Female | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Nitroso Compounds - therapeutic use | Mice, Inbred C57BL | Pancreatic Neoplasms - pathology | Albumin-Bound Paclitaxel - pharmacology | Melanoma, Experimental - pathology | Serum Albumin, Human - pharmacokinetics | Paclitaxel - therapeutic use | Neoplasms - drug therapy | Drug Synergism | Serum Albumin, Human - therapeutic use | Albumins - pharmacokinetics | Albumins - pharmacology | Animals | Serum Albumin, Human - pharmacology | Cell Line, Tumor | Mice | Mice, Inbred BALB C | Nitroso Compounds - pharmacokinetics | Neoplasms - pathology | Nitric Oxide - metabolism | Drugs | Drug delivery systems | Melanoma | Albumin | Permeability | Antineoplastic agents | Vehicles | Antimitotic agents | Chemotherapy | Colon cancer | Analysis | Pancreatic cancer | Cancer | Index Medicus
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 02/2013, Volume 166, Issue 1, pp. 66 - 74
The performance and safety of current antineoplastic agents, particularly water-insoluble drugs, are still far from satisfactory. For example, the currently... 
N-(2-hydroxypropyl)methacrylamide (HPMA) | Biodegradable multiblock copolymer | Paclitaxel | Ovarian cancer | MOLECULAR-WEIGHT | N-(2-hydroxypropyl)methactylamide (HPMA) | CANCER | CHEMISTRY, MULTIDISCIPLINARY | OVARIAN-CARCINOMA | CHEMOTHERAPY | TARGETING DELIVERY | N-(2-HYDROXYPROPYL)METHACRYLAMIDE COPOLYMERS | BODY DISTRIBUTION | CONJUGATE | PHARMACOLOGY & PHARMACY | IN-VIVO EVALUATION | CREMOPHOR EL | Molecular Weight | Nanoparticles - chemistry | Paclitaxel - chemical synthesis | Biocompatible Materials - chemistry | Humans | Ovarian Neoplasms - pathology | Acrylic Resins - chemical synthesis | Paclitaxel - pharmacokinetics | Drug Carriers - chemistry | Biocompatible Materials - chemical synthesis | Tissue Distribution | Paclitaxel - chemistry | Antineoplastic Agents, Phytogenic - administration & dosage | Acrylic Resins - pharmacokinetics | Female | Antineoplastic Agents, Phytogenic - therapeutic use | Paclitaxel - administration & dosage | Antineoplastic Agents, Phytogenic - pharmacokinetics | Ovarian Neoplasms - drug therapy | Cell Survival - drug effects | Paclitaxel - analogs & derivatives | Drug Carriers - chemical synthesis | Acrylic Resins - chemistry | Paclitaxel - therapeutic use | Acrylamides - chemistry | Xenograft Model Antitumor Assays | Acrylic Resins - therapeutic use | Animals | Mice, Nude | Cell Line, Tumor | Mice | Acrylamides - chemical synthesis | Drugs | Drug delivery systems | Dosage and administration | Vehicles | Index Medicus | Ascites | paclitaxel | biodegradable multiblock copolymer | ovarian cancer
Journal Article
Cancer, ISSN 0008-543X, 12/2018, Volume 124, Issue 24, pp. 4667 - 4675
This randomized phase 2 trial compares the efficacy and safety of second‐line nanoparticle albumin‐bound (nab)‐paclitaxel with or without CC‐486, an oral... 
advanced | second‐line | safety | survival | nonsquamous | non‐small cell lung cancer (NSCLC) | CC‐486 (oral 5‐azacitidine) | 5‐azacytidine | nanoparticle albumin‐bound paclitaxel (nab‐paclitaxel) | second-line | CC-486 (oral 5-azacitidine) | 5-azacytidine | nanoparticle albumin-bound paclitaxel (nab-paclitaxel) | non-small cell lung cancer (NSCLC) | MULTICENTER | CREMOPHOR-FREE | ORAL AZACITIDINE | DOCETAXEL | TRIAL | ONCOLOGY | WEEKLY NAB-PACLITAXEL | 1ST-LINE THERAPY | NIVOLUMAB | ABI-007 | MYELODYSPLASTIC SYNDROMES | Lung Neoplasms - drug therapy | Azacitidine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Drug Administration Schedule | Administration, Oral | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Paclitaxel - adverse effects | Albumins - administration & dosage | Male | Treatment Outcome | Disease-Free Survival | Albumins - adverse effects | Antibodies, Monoclonal - administration & dosage | Aged, 80 and over | Adult | Female | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Paclitaxel - administration & dosage | Azacitidine - administration & dosage | Slopes | Azacytidine | Toxicity | Lung | Lung cancer | Albumin | Disease control | Patients | Survival | Nanoparticles | Confidence intervals | Randomization | Reagents | Paclitaxel | Safety | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 3/2008, Volume 108, Issue 2, pp. 241 - 250
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2000, Volume 18, Issue 12, pp. 2354 - 2362
Purpose: To confirm the promising phase II results of docetaxel monotherapy, this phase III trial was conducted of chemotherapy for patients with advanced... 
ONCOLOGY | PACLITAXEL
Journal Article
by Meng, H and Wang, MY and Liu, HY and Liu, XS and Situ, A and Wu, B and Ji, ZX and Chang, CH and Nel, AE
ACS NANO, ISSN 1936-0851, 04/2015, Volume 9, Issue 4, pp. 3540 - 3557
Recently, a commercial albumin-bound paclitaxel (PTX) nanocarrier (Abraxane) was approved as the first new drug for pancreatic ductal adenocarcinoma in almost... 
SUPPORTED MEMBRANES | paclitaxel | PHYSICAL-PROPERTIES | synergy | mesoporous silica nanoparticle | VIVO | NAB-PACLITAXEL | MATERIALS SCIENCE, MULTIDISCIPLINARY | CHEMISTRY, PHYSICAL | NANOSCIENCE & NANOTECHNOLOGY | MODEL | CYTIDINE DEAMINASE | CHEMISTRY, MULTIDISCIPLINARY | OVERCOME DRUG-RESISTANCE | co-delivery | pancreatic cancer | IN-VITRO | ratiometric | gemcitabine | BILAYERS PROTOCELLS | NANOTECHNOLOGY | Albumins - chemistry | Deoxycytidine - chemistry | Paclitaxel - pharmacology | Pancreatic Neoplasms - metabolism | Nanoparticles - chemistry | Humans | Deoxycytidine - pharmacology | Antineoplastic Agents - therapeutic use | Drug Carriers - chemistry | Pancreatic Neoplasms - drug therapy | Albumins - therapeutic use | Paclitaxel - chemistry | Deoxycytidine - therapeutic use | Female | Antineoplastic Agents - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Pancreatic Neoplasms - pathology | Silicon Dioxide - chemistry | Antineoplastic Agents - chemistry | Paclitaxel - therapeutic use | Drug Synergism | Albumins - pharmacology | Animals | Cell Transformation, Neoplastic | Cytidine Deaminase - metabolism | Cell Line, Tumor | Mice | Lipid Bilayers - chemistry | Porosity | Deoxycytidine - analogs & derivatives | Index Medicus | Drugs | Effectiveness | Metabolites | Biocompatibility | Lipids | Nanostructure | Tumors | Cancer
Journal Article
Biomaterials, ISSN 0142-9612, 2011, Volume 32, Issue 31, pp. 8010 - 8020
Abstract Targeted delivery of therapeutic nanoparticles in a disease-specific manner represents a potentially powerful technology especially when treating... 
Advanced Basic Science | Dentistry | Chemotherapy | Aptamer | Drug delivery | Nanoparticle | Nucleolin | Paclitaxel | PRIMARY BRAIN-TUMORS | VITRO | MATERIALS SCIENCE, BIOMATERIALS | GLIOBLASTOMA-MULTIFORME | ENGINEERING, BIOMEDICAL | GLIOMA GROWTH | CELL-SURFACE | BIODISTRIBUTION | ANTITUMOR-ACTIVITY | IN-VIVO EVALUATION | Injections, Intravenous | Paclitaxel - pharmacology | Nanoparticles - chemistry | Humans | Oligodeoxyribonucleotides - chemical synthesis | Oligodeoxyribonucleotides - chemistry | Polyethylene Glycols - chemistry | Paclitaxel - pharmacokinetics | Aptamers, Nucleotide - chemical synthesis | Drug Delivery Systems | Glioma - pathology | Surface Properties - drug effects | Inhibitory Concentration 50 | Paclitaxel - administration & dosage | Aptamers, Nucleotide - pharmacology | Photoelectron Spectroscopy | Tissue Distribution - drug effects | Lactic Acid - chemistry | Magnetic Resonance Spectroscopy | Electrophoresis, Polyacrylamide Gel | Kaplan-Meier Estimate | Aptamers, Nucleotide - chemistry | Rats | Treatment Outcome | Static Electricity | Paclitaxel - therapeutic use | Particle Size | Animals | Mice, Nude | Polyglycolic Acid - chemistry | Cell Proliferation - drug effects | Mice | Oligodeoxyribonucleotides - pharmacology | Glioma - drug therapy | Drugs | Nanoparticles | Urea | Drug delivery systems | Biological products | Gliomas | Brain tumors | Vehicles | Index Medicus
Journal Article
Pharmaceutical Research, ISSN 0724-8741, 3/2015, Volume 32, Issue 3, pp. 1002 - 1016
Albumin nanoparticles have been explored as a promising delivery system for various therapeutic agents. One limitation of such formulations is their poor... 
Biochemistry, general | Biomedical Engineering | colloidal stability | paclitaxel | Biomedicine | Pharmacy | Medical Law | Pharmacology/Toxicology | pharmacokinetic | liposome | albumin nanoparticle | VITRO | COMPLEX MICELLES | DRUG-DELIVERY | HUMAN SERUM-ALBUMIN | CHEMISTRY, MULTIDISCIPLINARY | POLYMERIC NANOPARTICLES | FORMULATIONS | BOUND PACLITAXEL | PHARMACOLOGY & PHARMACY | POLYETHYLENE-GLYCOL | IN-VIVO EVALUATION | BLOCK-COPOLYMER | Albumins - chemistry | Injections, Intravenous | Paclitaxel - pharmacology | Albumin-Bound Paclitaxel | Humans | Half-Life | Male | Melanoma, Experimental - metabolism | Polyethylene Glycols - chemistry | Paclitaxel - pharmacokinetics | Breast Neoplasms - metabolism | Nanoparticles | Tissue Distribution | Paclitaxel - chemistry | Antineoplastic Agents, Phytogenic - administration & dosage | Lipids - chemistry | G2 Phase Cell Cycle Checkpoints - drug effects | MCF-7 Cells | Female | Paclitaxel - administration & dosage | Antineoplastic Agents, Phytogenic - pharmacokinetics | Nanomedicine | Cell Survival - drug effects | Drug Stability | Solubility | Melanoma, Experimental - pathology | Antineoplastic Agents, Phytogenic - chemistry | Technology, Pharmaceutical - methods | Chemistry, Pharmaceutical | Particle Size | Animals | Breast Neoplasms - pathology | Mice | Mice, Inbred BALB C | Liposomes | Antineoplastic Agents, Phytogenic - pharmacology | Thin films | Chemotherapy | Analysis | Paclitaxel | Albumin | Drugstores | Dielectric films | Chromatography | Cancer | Proteins | Drug delivery systems | Pharmaceutical sciences | Tumors | Index Medicus
Journal Article
Journal Article